Correspondence to letter to the editor on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma” Hyung Seok Kim, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun Clinical and Molecular Hepatology.2026; 32(1): e103. CrossRef
Metabolites involvement in the growth and spread of liver cancer Anurag Kumar Gautam, Vipin Kumar, Archana Bharti Sonkar, Amita Singh, Deepankar Yadav, Nitin Rajan, Pranesh Kumar, Sanjay Singh, Sudipta Saha, Vijayakumar Mahalingam Rajamanickam Liver Research.2025; 9(4): 286. CrossRef
Correspondence to editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma” Su Bin Lim, Hyo Jung Cho Clinical and Molecular Hepatology.2024; 30(4): 1009. CrossRef
Comparative effectiveness of immunotherapy versus lenvatinib in advanced hepatocellular carcinoma: A real-world analysis using target trial emulation Joseph C. Ahn, Wee Han Ng, Yee Hui Yeo, Hyun-Seok Kim, Yun Wang, Hirsh Trivedi, Walid S. Ayoub, Alexander Kuo, Nicole Rich, Neehar D. Parikh, Ghassan K. Abou-Alfa, Kevin Sheng-Kai Ma, Amit G. Singal, Ju Dong Yang Hepatology.2026; 83(2): 249. CrossRef
Liver Transplantation Following Immune Checkpoint Inhibitor Therapy: What Do We Need to Know from Clinical and Immunological Perspective? Hee Sun Cho, Soon Kyu Lee International Journal of Molecular Sciences.2026; 27(6): 2680. CrossRef
Survival benefits of non‑surgical triple therapy in hepatocellular carcinoma with inferior vena cava/right atrial tumor thrombus: A retrospective analysis from a multidisciplinary team Peng Tang, Jin Li, Jiayu Duan, Xin Wang, Jin Zhou, Yu Yang, Yong Zeng Oncology Letters.2026; 32(3): 1. CrossRef
Disparities in Immunotherapy Use Prior to First-Line Approval for Metastatic Hepatocellular Carcinoma in the United States Manav Shah, Abdullah Khalid, Oliver Standring, Neda Amini, Lyudmyla Demyan, Shruti Koti, Emma Gazzara, Grace Wu, Nandan Vithlani, Danielle DePeralta, Sepideh Gholami, Matthew Weiss Onco.2025; 5(1): 6. CrossRef
Current Landscape of Adoptive Cell Therapy and Challenge to Develop “Off‐The‐Shelf” Therapy for Hepatocellular Carcinoma Seung Kak Shin, Yuta Mishima, Yoonseok Lee, Oh Sang Kwon, Ju Hyun Kim, Yun Soo Kim, Shin Kaneko Journal of Gastroenterology and Hepatology.2025; 40(4): 791. CrossRef
Landscape of T-cell exhaustion heterogeneity and HBV integration in virus-related HCC revealed by whole-exome, transcriptome, and single-cell sequencing Soon Kyu Lee, Jinyeong Lim, Joo Yeon Jhun, Jeonghyeon Moon, Hye Seon Kim, Jong Young Choi, Ho Joong Choi, Young Kyoung You, Ji Won Han, Pil Soo Sung, Kwon Yong Tak, Seung Kew Yoon, Woong-Yang Park, Mi-La Cho, Jeong Won Jang JHEP Reports.2025; 7(11): 101518. CrossRef
Efficacy and safety of stereotactic body radiation therapy combined with targeted agents and immunotherapies in hepatocellular carcinoma: a systematic review and meta-analysis Shuaihao Hou, Suqin Hu, Qiong Wu, Haonan Sun, Zhongxuan Fang, Rong Sun, Liqun Wang, Bin Zhou BMC Cancer.2025;[Epub] CrossRef
T cell-related ubiquitination genes as prognostic indicators in hepatocellular carcinoma Chaobo Chen, Zheng Chen, Zheyu Zhou, Hui Ye, Shaohui Xiong, Weidong Hu, Zipeng Xu, Chen Ge, Chunlong Zhao, Decai Yu, Jiapei Shen Frontiers in Immunology.2024;[Epub] CrossRef
CCL5/CCR5/CYP1A1 pathway prompts liver cancer cells to survive in the combination of targeted and immunological therapies Yafei Wang, Biao Gao, Tianyu Jiao, Wenwen Zhang, Huizhong Shi, Hao Jiang, Xuerui Li, Junfeng Li, Xinlan Ge, Ke Pan, Chonghui Li, Guankun Mao, Shichun Lu Cancer Science.2024; 115(11): 3552. CrossRef
An Early Increase in IL-10 and TNF-α Levels Following Atezolizumab Plus Bevacizumab Treatment Predicts Survival in Advanced Hepatocellular Carcinoma Patients: A Prospective Cohort Study Soon Kyu Lee, Soon Woo Nam, Ji Won Han, Jung Hyun Kwon Cancers.2024; 16(20): 3543. CrossRef
Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison Yuri Cho, Bo Hyun Kim, Joong-Won Park Clinical and Molecular Hepatology.2023; 29(2): 252. CrossRef
The prime time for management of hepatocellular carcinoma in Hong Kong Landon L. Chan, Stephen L. Chan Clinical and Molecular Hepatology.2023; 29(2): 345. CrossRef
What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea? Min Kyung Park, Yoon Jun Kim Clinical and Molecular Hepatology.2023; 29(2): 332. CrossRef
First
Prev
